Daewon to expand indications of felubiprofen

Published: 2009-08-31 06:57:00
Updated: 2009-08-31 06:57:00
The Korea Food and Drug Administration gave its nod to the local clinical trials of Daewon’s felubiprofen (brandname: Peluvi), a nonsteroidal anti-inflammatory drug, aiming at expanding indications, such as lumbago.

Daewon said the local clinical trial is to be completed in the latter half of ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.